Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals focuses on neuroscience and provides FDA-approved treatments for conditions such as Parkinson's disease psychosis and Rett syndrome, while developing novel therapies for neurological disorders.

COM:ACADIA

Acadia Pharmaceuticals

Last Close

16.18

22/11 21:00

Market Cap

2.72B

Beta: -

Volume Today

1.40M

Avg: -

Financials Not Available